ARCHIVES

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

This article is from The Cancer Letter archive.

Vol. 26 No. 11 | November 28, 2003

Download PDF Visit The Full Archive

Related Articles

Outside Experts Might Lengthen NDA Approval, Peck Asserts

September 7, 1990

Diet/Cancer Product ad Seminar Consensus: It’s Okay When Limited To Categories Of Food

November 7, 1986

Drugs and Targets: EU approves Imbruvica in MCL, CLL

October 24, 2014

Arthur James, Ohio Founder Of Research Institute, Dead.

October 26, 2001

Cancer Center To Get Recommended Funding, Restoration of 1990-91 Cuts, NCI Tells Directors

July 24, 1992

New Staff Proposals For Comprehensive Center Recognition Considered By NCAB

January 19, 1979